COLLABORATIONS AND ALLIANCES (Detail Textuals 2) (USD $)	3 Months Ended								12 Months Ended			1 Months Ended	3 Months Ended	12 Months Ended			1 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2008 Daiichi Sankyo Tivantinib Agreement	Dec. 31, 2012 Daiichi Sankyo Tivantinib Agreement	Dec. 31, 2012 Daiichi Sankyo Tivantinib Agreement	Dec. 31, 2011 Daiichi Sankyo Tivantinib Agreement	Dec. 31, 2010 Daiichi Sankyo Tivantinib Agreement	Jan. 31, 2013 Daiichi Sankyo Tivantinib Agreement Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received												$ 60,000,000
Potential additional development and sales milestone payments												560,000,000
Cumulative share of phase 3 collaboration costs														63,800,000
Milestones earned														25,000,000			15,000,000
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received														38,800,000	10,600,000
Collaboration costs incurred recognized as contra-revenue														1,400,000	16,600,000	3,300,000
Advance drug purchases															5,400,000
Amount of drug purchases recognized as contra-revenue														2,500,000	2,900,000
Notice period for termination of contract prior to start of specified period														90 days
Notice period for termination of contract Post start of Phase 3 clinical trials														180 days
Prepaid phase 3 drug purchases															2,500,000
Research and development revenue	5,143,000	10,944,000	11,829,000	8,498,000	16,504,000	11,954,000	5,447,000	13,405,000	36,414,000	47,310,000	29,221,000			12,400,000	9,500,000	10,500,000
Contra revenue recognized														3,900,000	19,500,000	3,300,000
Deferred revenue													20,800,000	20,800,000	37,000,000
Previously estimated research and development revenue													4,700,000
Revised estimated research and development revenue													2,100,000
Reduction in previously estimated research and development revenue													$ 2,600,000